Hcc38

Archival FFPE tumor tissues were obtained from 195 ovarian and breast cancer patients who had signed the informed consents, and the study was approved by the Institutional Review Board of BGI Co., Ltd. 17 human cancer cells (HCC38, HCC1428, HCC1143, HCC1806, MX-1, HCC70, ZR-75-1, MDA-MB-453, MDA-MB-231, MDA-MB-361, MDA-MB-415, ZR-75-30, HS-578T, IGR-OV1, A2780, NCI/ADR-RES and OVCAR-4) and 3 matched-wildtype cell lines (HCC38BL, HCC1143BL and HCC1428BL) were purchased from the CoBioer Biosciences Co., Ltd. All cell lines have been verified by STR and were provided in the form of DNA status.

Two BC cells (BT549 and HCC38) and breast epithelial cells (MCF-10A) were purchased from COBIOER (Nanjing, China). These cells were maintained in Dulbecco’s modified eagle medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Invitrogen). Then these cells were cultivated at 37 ℃ under a humidified atmosphere with 5% CO₂.
For transfection, short-hairpin RNA (shRNA) against circPLK1 (sh-circPLK1), circPLK1 overexpression vector (circPLK1), pcDNA3.0-IGF1 overexpression plasmid (pcDNA3.0-IGF1), miR-4500 mimic (miR-4500), miR-4500 inhibitor (anti-miR-4500), and negative controls (sh-NC, Vector, pcDNA3.0-NC, miR-NC, and anti-NC) were obtained from RiboBio (Guangzhou, China). Transient transfection was performed using the Lipofectamine 3000 reagent (Invitrogen).